SCHEMBL963410

SCHEMBL963410

CC(C)Nc1ccccc1CO

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
TDP1 Q9NUW8 2/20 0.41
APOBEC3G Q9HC16 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
PDCD1 Q15116 1/20 0.37
CD274 Q9NZQ7 1/20 0.37
AOC1 P19801 2/20 0.37
AOC3 Q16853 2/20 0.37
LMNA P02545 1/20 0.36
CYP3A4 P08684 1/20 0.36
THRB P10828 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36
RECQL P46063 1/20 0.36
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11558262 0.84 IDO1 (0.42) IDO1ALDH1A1TDP1L3MBTL1AOC1
SCHEMBL28108556 0.81 IDO1 (0.40) IDO1ALDH1A1HPGDTDP1L3MBTL1
SCHEMBL30316736 0.81 ALDH1A1 (0.46) IDO1ALDH1A1TDP1
SCHEMBL8097565 0.81 ALDH1A1 (0.46) IDO1ALDH1A1TDP1
SCHEMBL22133452 0.79 AOC1 (0.58) IDO1ALDH1A1TDP1L3MBTL1AOC1
SCHEMBL13689141 0.78 ADRA2B (0.42) IDO1ALDH1A1TDP1L3MBTL1AOC1
SCHEMBL24260299 0.77 CYP1A2 (0.41) IDO1ALDH1A1TDP1L3MBTL1MDM4
SCHEMBL11828241 0.77 PTGS2 (0.55) TDP1L3MBTL1
SCHEMBL24260301 0.77 L3MBTL1 (0.42) IDO1ALDH1A1TDP1L3MBTL1TSHR
SCHEMBL15981422 0.77 IDO1 (0.40) IDO1ALDH1A1TDP1L3MBTL1AOC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9873692-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2018-01-23 US disclosed
US-20170334901-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-11-23 US disclosed
US-9630960-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2017-04-25 US disclosed
US-20160376264-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-12-29 US disclosed
US-9402840-B2 Crystalline form of a quinolinone-carboxamide compound THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-08-02 US disclosed
US-9353106-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-05-31 US disclosed
US-20160095849-A1 CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND THERAVANCE BIOPHARMA R&D IP, LLC (US) 2016-04-07 US disclosed
US-20150291580-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-10-15 US disclosed
US-9126994-B2 Crystalline form of a quinolinone-carboxamide compound THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-09-08 US disclosed
US-8962653-B2 Quinolinone-carboxamide compounds as 5-HT4 receptor agonists THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-02-24 US disclosed
US-5753673-A Quinolinecarboxylic acid derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 1998-05-19 US disclosed
US-5733917-A GASTROINTESTINAL DISORDERS TAISHO PHARMACEUTICAL CO., LTD. (JP) 1998-03-31 US disclosed
EP-0748808-A1 HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO. LTD (JP) 1996-12-18 EP disclosed
US-5571820-A QUINOLINE DERIVATIVES, TREATMENT OF GASTROINTESTINAL DISORDERS CAUSED BY DECREASED MOTILITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 1996-11-05 US disclosed
EP-0710662-A1 QUINOLINECARBOXYLIC ACID DERIVATIVE TAISHO PHARMACEUTICAL CO. LTD (JP) 1996-05-08 EP disclosed
EP-0354788-B1 Novel imidazole derivatives NIPPON CHEMIPHAR CO (JP) 1995-09-13 EP disclosed
EP-0670319-A1 HETEROCYCLIC COMPOUND Thaisho Pharmaceutical Co., Ltd (JP) 1995-09-06 EP disclosed
US-5180836-A Antiulcer agents NIPPON CHEMIPHAR CO., LTD. (JP) 1993-01-19 US disclosed
US-5082943-A Antiulcer NIPPON CHEMIPHAR CO., LTD. (JP) 1992-01-21 US disclosed
EP-0354788-A1 Novel imidazole derivatives NIPPON CHEMIPHAR CO., LTD. (JP) 1990-02-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160095849-A1 CRYSTALLINE FORM OF A QUINOLINONE-CARBOXAMIDE COMPOUND HTR5A, HTR4, HTR2C IDO1 269/4885ALDH1A1 2379/4885HPGD 3161/4885
US-20160376264-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A IDO1 299/4885ALDH1A1 2540/4885HPGD 1386/4885
US-20150291580-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A IDO1 299/4885ALDH1A1 2540/4885HPGD 1386/4885
US-20170334901-A1 QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS HTR4, HTR5A, HTR1A IDO1 299/4885ALDH1A1 2540/4885HPGD 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.